NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The US Food and Drug Administration (FDA) has published information about an ongoing safety review of tiotropium (Spiriva®) The manufacturer, Boehringer Ingelheim, recently informed the FDA that ongoing safety […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The MHRA has published the findings of its review of LABAs (salmeterol and formoterol) in asthma, in the January issue of Drug Safety Update (7th January 2008). Background Concerns […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. In an internal memorandum, drug safety staff at the FDA in the USA have commented that salmeterol “may have an unfavorable risk benefit ratio in the treatment of pediatric […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. What is this about? NICE has published technology appraisals covering corticosteroids for asthma in children and the place of omalizumab▼ in uncontrolled asthma. What do they say about inhaled […]

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. A study published in the American Journal of Respiratory Critical Care provides further information about the risks associated with using inhaled corticosteroids in chronic obstructive pulmonary disease (COPD) What […]